ReviewNigerian medical journal : journal of the Nigeria Medical Association
Opioid Addiction Medicine in Nigeria: Bridging Clinical Gaps in a Silent Epidemic-A Narrative Review.
Review in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid use disorder (OUD) is an emerging public-health challenge in Nigeria, driven largely by non-medical use of tramadol and codeine and compounded by limited access to evidence-based care. This narrative review synthesises evidence on the epidemiology, patterns, harms and treatment gaps for OUD in Nigeria and identifies priorities for policy and research. We searched PubMed/MEDLINE, Embase, PsycINFO, the Cochrane Library, African Journals Online, Google Scholar and grey literature from 2005 to 2024 for Nigerian data on non-medical opioid use, clinical harms, opioid agonist therapy (OAT) services, barriers and community supports. Findings were thematically synthesised using Braun and Clarke's framework, with quality appraisal using Joanna Briggs Institute tools and the SANRA scale. Thirty studies were included. The 2019 national drug use survey estimated past-year opioid use at 4.7% (approximately 4.6 million people), with institution-based surveys reporting high lifetime misuse among undergraduates. Reported harms included overdose, seizures, psychiatric comorbidity and injectable pentazocine dependence with severe soft-tissue infections. OAT availability remains highly centralised, with limited community recovery infrastructure. Nigeria's OUD burden is substantial but unevenly characterised, highlighting the need to decentralise OAT, integrate addiction training, strengthen surveillance and expand community supports.
Indexed as
Identifiers
42488855PMC13391113What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.